Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.

Autor: Thistlethwaite FC; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK. fiona.thistlethwaite@christie.nhs.uk.; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK. fiona.thistlethwaite@christie.nhs.uk., Gilham DE; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK., Guest RD; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK.; Cellular Therapeutics Limited, Grafton Street, Manchester, UK., Rothwell DG; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Withington, Manchester, UK., Pillai M; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK.; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK., Burt DJ; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Withington, Manchester, UK., Byatte AJ; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK., Kirillova N; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK.; Cellular Therapeutics Limited, Grafton Street, Manchester, UK., Valle JW; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK.; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK., Sharma SK; University College London (UCL) Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, UK., Chester KA; University College London (UCL) Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, UK., Westwood NB; Cancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK., Halford SER; Cancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK., Nabarro S; Cancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK., Wan S; Cancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK., Austin E; Stem Cells and Immunotherapy, National Health Service Blood and Transplant (NHSBT) Liverpool Centre, Speke, Liverpool, UK., Hawkins RE; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK.; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2017 Nov; Vol. 66 (11), pp. 1425-1436. Date of Electronic Publication: 2017 Jun 28.